Oncologica, a leading
laboratory in genetic testing
is now providing a rapid COVID-19 testing/screening service with a
48h turnaround time

Forward planning and mitigating Covid-19 risk for businesses

The return to work presents a major challenge for employers, employees and their families.

The inability to identify coronavirus infections will have a significant impact in the work place resulting in staff absences and reduced economic productivity. Protecting workers and their families from the risk of infection needs to be a top priority for all employers.

 

 

The Problem

Many people can have the virus but not show any symptoms. This means they can infect people around them unknowingly.

The relaxation of quarantine measures will result in clusters and spikes of infection. This will present a challenge in being able to distinguish common cold and flu symptoms from those of coronavirus

The application of measures such as sanitation and social distancing inside offices and factories may not be sufficient to ensure the safety of workers and customers and in some environments may be very expensive or not possible.

The Solution

Regular testing in the work place will help to maintain a COVID-19 protected enviroment

Testing & Corporate protection plans

To mitigate the impact of coronavirus and provide a Covid-19 protected environment, facilitating strong and fast recovery and to maintain competitiveness, Oncologica is now offering a rapid Covid-19 testing/screening service with a 48h turnaround time.

* Currently accepting pre-orders. Due to the high demand, the next available starting date for the service will be the 11th of May 2020. Please contact us for more information

INSTANT QUOTE

More information on our COVID-19 testing service.

We’re helping to protect businesses of any size from £100 per employee per month

The information transmitted is used exclusively to process your request. By submitting this form you accept the terms and conditions including our Privacy Policy. At any time you can ask for your personal data to be deleted and removed.

This form is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Accept Privacy Policy

How the test works

The organization decides the testing strategy required (e.g. single one-off tests for symptomatic individuals or regular screening).

Oncologica provides swabs and transport tubes to the organisation and pre-paid envelopes for their return. Alternatively, the organisation may choose arrange a courier service.

Once samples arrive at our laboratories, the virus is inactivated and RNA extracted from the swab.

Analysis of extracted RNA is performed using a validated methodology (PCR) to confirm the presence or absence of the Coronavirus (COVID-19).

Results are interpreted by Oncologica and sent back electronically to the Organisation within 48h

Oncologica® is a leading precision oncology certified laboratory based in the prestigious Chesterford Research Park, Cambridge, UK.

Oncologica was established in 2014 to address precision oncology/personalised medicine testing for cancer patients using high complexity molecular platforms. Oncologica is a United Kingdom UKAS accredited (ISO15189) and United States CLIA certified laboratory enabling us to undertake high complexity molecular testing.

Due to Covid-19 and the very high risk of this disease to immunocompromised cancer patients Oncologica has now utilised its platforms to perform high throughput Covid-19 testing.

We have now extended provision of Covid-19 testing to the wider community.

What is the difference between the CoronaFocus PCR test and the antibody test?

THE SWAB/PCR TEST

This test detects the presence of the virus on the swabs taken from the throat and nose of the subject. Therefore it tests for active infections, meaning that if the subject is infected he or she could be transmitting the virus to others.

This test plays an important role in controlling the spread of the virus in the workplace and the community.

THE ANTIBODY/BLOOD TEST

This test detects the presence of antibodies in the blood which indicates that the person has had the infection in the past . These tests are presently unreliable and furthermore cannot be used to monitor and control active transmission of the virus. However they can provide useful information about exposure to the virus in the community.

Oncologica is currently reviewing and assessing the reliability of antibody tests and will be providing this testing service in the near future.

General enquiries

One of our consultants will contact you within 24h

The information transmitted is used exclusively to process your request. By submitting this form you accept the terms and conditions including our Privacy Policy. At any time you can ask for your personal data to be deleted and removed.

This form is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Accept Privacy Policy

s

Note to patients: All contents on this page are for informational purposes. Decisions regarding medical treatments and diagnoses must always be made in consultation with your treating clinician.

Oncologica® UK ltd. is a registered Medical Laboratory accredited to ISO15189:2012 standards.

Accreditation number: 9376 (click here to see accreditation document)

Suite 15-16 The Science Village, Chesterford Research Park, Little Chesterford, Cambridge, CB10 1XL
+44 (0) 1223 785327

Privacy Policy